Reference

[1]   C. P. Stewart, B. W., Wild, "World Cancer Report 2014- IARC WHO," *IARC Nonserial Publ.*, p. 630, 2014.

[2]   R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2019," *CA. Cancer J. Clin.*, vol. 69, no. 1, pp. 7–34, 2019, doi: 10.3322/caac.21551.

[3]   F. E. Vera-Badillo, M. Al-Mubarak, A. J. Templeton, and E. Amir, "Benefit and harms of new anti-cancer drugs," *Curr. Oncol. Rep.*, vol. 15, no. 3, pp. 270–275, 2013, doi: 10.1007/s11912-013-0303-y.

[4]   B. Seruga, A. J. Templeton, F. E. V. Badillo, A. Ocana, E. Amir, and I. F. Tannock, "Under-reporting of harm in clinical trials," *Lancet Oncol.*, vol. 17, no. 5, pp. e209–e219, 2016, doi: 10.1016/S1470-2045(16)00152-2.

[5]   I. Khan, M. A. Shareef, and C. G. Kumar, "An overview on the synthetic and medicinal perspectives of indenopyrazoles," *Eur. J. Med. Chem.*, vol. 178, pp. 1–12, 2019, doi: 10.1016/j.ejmech.2019.05.070.

[6]   S. Asirvatham, B. V. Dhokchawle, and S. J. Tauro, "Quantitative structure activity relationships studies of non-steroidal anti-inflammatory drugs: A review," *Arab. J. Chem.*, vol. 12, no. 8, pp. 3948–3962, 2019, doi: 10.1016/j.arabjc.2016.03.002.

[7]   S. K. Singh, N. Dessalew, and P. V. Bharatam, "3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors," *Eur. J. Med. Chem.*, vol. 41, no. 11, pp. 1310–1319, 2006, doi: 10.1016/j.ejmech.2006.06.010.

[8]   A. Ece and F. Sevin, "CHEMISTRY The discovery of potential cyclin A / CDK2 inhibitors : a combination of 3D QSAR pharmacophore modeling , virtual screening , and molecular docking studies," 2013, doi: 10.1007/s00044-013-0571-y.

[9]   M. Shahlaei, A. Fassihi, L. Saghaie, E. Arkan, A. Madadkar-Sobhani, and A. Pourhossein, "Computational evaluation of some indenopyrazole derivatives as anticancer compounds; application of QSAR and docking methodologies," *J. Enzyme Inhib. Med. Chem.*, vol. 28, no. 1, pp. 16–32, 2013, doi: 10.3109/14756366.2011.618991.

[10]   S. K. G. Md. Muzaffar-ur-Rehman* Leander Corrie Bejjenki Pavan Kumar, "3D-Qsar Studies of Indenopyrazole As Cdk4 Inhibitors With Comfa and Comsia Methods," *Indo Am. J. Pharm. Sci.*, vol. 4, no. 09, pp. 2981–2993, 2017, doi: 10.5281/ZENODO.893297.

[11]   V. Saravanan and P. T. V. Lakshmi, "ACPP: A web server for prediction and design of anti-cancer peptides," *Int. J. Pept. Res. Ther.*, vol. 21, no. 1, pp. 99–106, 2015, doi: 10.1007/s10989-014-9435-7.

[12]   F. Rahman, "Implementation of Simulated Annealing-Support Vector Machine on QSAR Study of Fusidic Acid Derivatives as Anti-Malarial Agent."

[13]   M. F. Rizqi, I. Kurniawan, and R. R. Septiawan, "Implementasi Metode Simulated Annealing - Support Vector Machine pada Studi QSAR dari Senyawa Turunan Indenopyrazole Sebagai Antikanker," 2019.

[14]   K. Luebke and C. Weihs, "Testing a simulated annealing algorithm in a classification problem," *Lect. Notes Comput. Sci. (including Subser. Lect. Notes Artif. Intell. Lect. Notes Bioinformatics)*, vol. 2827, pp. 61–70, 2003, doi: 10.1007/978-3-540-39816-5_6.

[15]   A. D. Perwita, C. Fatichah, and R. Soelaiman, "Uji Kinerja Penggabungan Algoritma Support Vector Machine dan Simulated Annealing Pada Permasalahan Klasifikasi Pola," vol. 2, no. 1, pp. 1–5, 2013.

[16]   Y. Li *et al.*, "Insights on structural characteristics and ligand binding mechanisms of CDK2," *Int. J. Mol. Sci.*, vol. 16, no. 5, pp. 9314–9340, 2015, doi: 10.3390/ijms16059314.

[17]   G. R. Rosania and Y. T. Chang, "Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors," *Expert Opin. Ther. Pat.*, vol. 10, no. 2, pp. 215–230, 2000, doi: 10.1517/13543776.10.2.215.

[18]   S. Samanta, B. Debnath, A. Basu, S. Gayen, K. Srikanth, and T. Jha, "Exploring QSAR on 3-aminopyrazoles as antitumor agents for their inhibitory activity of CDK2/cyclin A," *Eur. J. Med. Chem.*, vol. 41, no. 10, pp. 1190–1195, 2006, doi: 10.1016/j.ejmech.2006.05.007.

[19]   R. P. Sheridan, "Debunking the idea that ligand efficiency indices are superior to pIC50 as QSAR activities," *J. Chem. Inf. Model.*, vol. 56, no. 11, pp. 2253–2262, 2016, doi: 10.1021/acs.jcim.6b00431.

[20]   S. Cotesta *et al.*, "Virtual screening to enrich a compound collection with CDK2 inhibitors using docking, scoring, and composite scoring odels," *Proteins Struct. Funct. Genet.*, vol. 60, no. 4, pp. 629–643, 2005, doi: 10.1002/prot.20473.

[21]   A. Allouche, "Software News and Updates Gabedit — A Graphical User Interface for Computational Chemistry Softwares," *J. Comput. Chem.*, vol. 32, pp. 174–182, 2012, doi: 10.1002/jcc.

[22]   I. Kurniawan, M. Rosalinda, and N. Ikhsan, "Implementation of ensemble methods on QSAR Study of NS3 inhibitor activity as anti-dengue agent," *SAR QSAR Environ. Res.*, vol. 31, no. 6, pp. 477–492, 2020, doi: 10.1080/1062936X.2020.1773534.

[23]   J. Benesty, J. Chen, and Y. Huang, "On the importance of the pearson correlation coefficient in noise reduction," *IEEE Trans. Audio, Speech Lang. Process.*, vol. 16, no. 4, pp. 757–765, 2008, doi: 10.1109/TASL.2008.919072.

[24]   M. Brusco, H. J. Stolze, M. Hoffman, and D. Steinley, "A simulated annealing heuristic for maximum correlation core/periphery partitioning of binary networks," *PLoS One*, vol. 12, no. 5, pp. 1–17, 2017, doi: 10.1371/journal.pone.0170448.

[25]   S. H. Zhan, J. Lin, Z. J. Zhang, and Y. W. Zhong, "List-Based Simulated Annealing Algorithm for Traveling Salesman Problem," *Comput. Intell. Neurosci.*, vol. 2016, 2016, doi: 10.1155/2016/1712630.

[26]   D. Henderson, S. H. Jacobson, and A. W. Johnson, "The Theory and Practice of Simulated Annealing," *Handb. Metaheuristics*, pp. 287–319, 2006, doi: 10.1007/0-306-48056-5_10.

[27]   A. H. Zhou *et al.*, "Traveling-salesman-problem algorithm based on simulated annealing and gene-expression programming," *Inf.*, vol. 10, no. 1, 2018, doi: 10.3390/info10010007.

[28]   G. S. K. Ranjan, A. Kumar Verma, and S. Radhika, "K-Nearest Neighbors and Grid Search CV Based Real Time Fault Monitoring System for Industries," *2019 IEEE 5th Int. Conf. Converg. Technol. I2CT 2019*, pp. 9–13, 2019, doi: 10.1109/I2CT45611.2019.9033691.

[29]   T. Gunasegaran and Y. N. Cheah, "Evolutionary cross validation," *ICIT 2017 - 8th Int. Conf. Inf. Technol. Proc.*, pp. 89–95, 2017, doi: 10.1109/ICITECH.2017.8079960.

[30]   N. De, *NEW APPROACHES IN TIME SERIES FORECASTING: METHODS, SOFTWARE, AND EVALUATION PROCEDURES TESIS DOCTORAL presentada para la obtención del*. 2013.

[31]   M. Sokolova, N. Japkowicz, and S. Szpakowicz, "Beyond accuracy, F-score and ROC: A family of discriminant measures for performance evaluation," *AAAI Work. - Tech. Rep.*, vol. WS-06-06, pp. 24–29, 2006, doi: 10.1007/11941439_114.

Lampiran